301015.SZ
百洋医药
SZSE · Healthcare · F 批发零售 · CN
CNY 24.87
−3.83%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 7.4B | 7.5B | 8.1B | 8.3B | 7.5B |
| Cost of Revenue | 4.6B | 4.7B | 5.2B | 5.5B | 5.4B |
| Gross Profit | 2.9B | 2.8B | 2.9B | 2.7B | 2.1B |
| Operating Expenses | |||||
| R&D Expense | 41.9M | 42.2M | 36.1M | 42.5M | 3.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 334.3M | 326.2M | 280.6M | 280.7M | 196.7M |
| Selling & Marketing Expense | 1.7B | 1.6B | 1.5B | 1.3B | 1.1B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 2.2B | 2.1B | 1.9B | 1.7B | 1.4B |
| Cost and Expenses | 6.8B | 6.8B | 7.2B | 7.3B | 6.8B |
| Operating Income (EBIT) | 785.1M | 736.3M | 977.7M | 1.0B | 674.3M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 773.3M | 723.0M | 966.6M | 1.0B | 668.5M |
| Income Tax Expense | 155.6M | 151.0M | 199.6M | 257.3M | 178.7M |
| Bottom Line | |||||
| Net Income | 513.6M | 474.7M | 691.6M | 712.1M | 506.6M |
| Earnings from Cont. Ops | 617.7M | 571.9M | 767.0M | 770.7M | 489.8M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 513.6M | 474.7M | 691.6M | 712.1M | 506.6M |
| Per Share | |||||
| Basic EPS | CN¥0.98 | CN¥0.90 | CN¥1.32 | CN¥1.36 | CN¥0.96 |
| Diluted EPS | CN¥0.98 | CN¥0.89 | CN¥1.28 | CN¥1.33 | CN¥0.96 |
| Revenue Per Share | CN¥14.43 | CN¥14.23 | CN¥15.45 | CN¥15.77 | CN¥14.23 |
| Shares | |||||
| Basic Shares Outstanding | 516.4M | 527.4M | 523.9M | 523.6M | 527.7M |
| Diluted Shares Outstanding | 516.4M | 527.4M | 523.9M | 523.6M | 527.7M |
| Profitability Metrics | |||||
| EBITDA | — | 833.2M | 1.0B | 1.1B | 704.3M |
| D&A | — | 97.0M | 69.1M | 62.9M | 30.0M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026